Damian Garde is a reporter for STAT, a leading health and science publication. His articles cover a wide range of topics in the biotech industry, including trends, company news, FDA approvals, and healthcare conferences. Damian's work has also been featured in the Boston Globe Technology section.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Damian Garde's coverage predominantly focuses on the healthcare and pharmaceutical industries, particularly biotechnology. He frequently cites data and press releases while also incorporating expert commentary.
To effectively engage Damian, offer insights backed by relevant data or provide access to industry experts who can offer nuanced perspectives on developments within the biotech, healthcare, and pharmaceutical sectors. Considering his focus on specific companies and deals, pitches should involve sources with direct knowledge of the events covered or deep expertise in similar occurrences within these industries.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Madison Muller, Damian Garde
US drug regulatory staffers are considering a more targeted approval for Eli Lilly & Co. 's experimental Alzheimer's disease treatment than the company wants, potentially limiting the market for a would-be blockbuster.
Pfizer Inc. Chief Executive Officer Albert Bourla said the pharma giant is pausing big acquisitions after spending $43 billion last year on buying Seagen Inc.
Pfizer Inc. Chief Executive Officer Albert Bourla said the pharma giant is pausing big acquisitions after spending $43 billion last year on buying Seagen Inc.
By: Jessica Nix, Fiona Rutherford, Damian Garde
Eli Lilly & Co. 's treatment for Alzheimer's disease works in at least some patients, according to a US advisory panel.
By: Fiona Rutherford, Jessica Nix, Damian Garde
Eli Lilly & Co.’s treatment for Alzheimer’s disease works in at least some patients, according to a US advisory panel.
By: Fiona Rutherford, Damian Garde, Jessica Nix
Eli Lilly & Co.'s drug for Alzheimer's drug's benefits outweigh its risks, U.S. drug regulatory advisers said, bringing the treatment's long path to the market closer to a successful end.
(Bloomberg) -- A gene therapy from Pfizer Inc. failed to improve motor function for patients with a rare, muscle-destroying disease in a key clinical trial, jeopardizing the future of a once-promising medicine.
The government’s new authority is limited to just 10 medicines purchased by Medicare, and manufacturers may charge more for years before negotiations kick in.
Merck & Co. won US approval for a pneumococcal vaccine that threatens to unseat one of Pfizer Inc. 's biggest franchises.
Merck & Co. won US approval for a pneumococcal vaccine that threatens to unseat one of Pfizer Inc.’s biggest franchises.
(833) 317-6278 
